This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

It has high antibacterial activity against most aerobic Gram-negative bacteria, inhibiting the synthesis of bacterial cell walls by highly binding to penicillin-binding protein (PBP3) on the cell membrane of sensitive aerobic Gram-negative bacteria. It does not induce bacteria to produce b-lactamase, and is highly stable to most b-lactamases produced by bacteria.